How Low Should You Target LDL-C?

Details & Video

Program Time: 30 minutes
Accreditation-CME Credits: This online 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.
Target Audience: General Practitioners
Program available until: October 18, 2019
Program Preview
Click image above to play the program preview.
To watch the full program, please login or register

Overview & Objectives

How Low Should You Target LDL-C?

Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:
  1. IDENTIFY The additional benefits of lowering LDL-C beyond the current target levels
  2. DISCUSS If LDL-C can be too low



Accreditation

This online 1-credit-per-hour Self-Learning program has been certified by the College of Family Physicians of Canada for up to 0.5 Mainpro+ credits.

This program was supported in part by educational funding from Amgen Canada.

Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login. Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.

Scientific Planning Committee

Scientific Planning Committee

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS

Associate Clinical Professor of Medicine,
McMaster University

Medical Director
Canadian Collaborative Research Network

View disclosures

Brampton, ON
Jeffrey Habert
Jeffrey Habert
MD, CCFP, FCFP

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine

View disclosures

Toronto, Ontario
Daniel Ngui
Daniel Ngui
BSc (P.T), MD, CFPC, FCFP

Clinical Associate Professor
University of British Columbia

Medical Director
Fraser Street Medical

View disclosures

Vancouver, ON
Marla Shapiro
Marla Shapiro
C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, NCMP

Professor, University of Toronto
Department of Family and Community Medicine

University Health Network
North York General, Mount Sinai

View disclosures

Toronto, Ontario
Robert P. Giugliano
Faculty
Robert P. Giugliano
MD, SM

Senior Investigator , TIMI Study Group
CV Medicine, Brigham and Women’s Hospital
Assoc Prof of Medicine, Harvard Medical School
View disclosures

Boston, MA

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Introduction2:14
What is a "typical" cholesterol value?0:55
What we have learned about LDL-C lowering.1:04
What we have learned from PROVE-IT.1:03
What we have learned from IMPROVE-IT.2:24
What we have learned from FOURIER.7:25
What we have learned from ODYSSEY Outcomes.3:44
Cost effectiveness of PCSK9 Inhibitors1:45
Lowering LDL-C: What should we aim for?1:56


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

  • O’Keefe JH et al. J Am Coll Cardiol. 2004;43:2142-2146.
  • Ballantyne CM. Am J Cardiol. 1998
  • O’Keefe JH et al, JACC 2004
  • Wiviott SD et al. J Am Coll Cardiol. 2005;46:1411-1416.
  • Cannon CP, Blazing MA, Giugliano RP, et al. NEJM. 2015;372(25):2387-2397
  • Cannon NEJM 2015;372:2387-97
  • Giugliano RP et al. JAMA Cardiol 2017; 2:547-55
  • Sabatine MS et al. Am Heart J 2016;173:94-101
  • Sabatine MS et al. New Engl J Med 2017;376:1713-22
  • Giugliano RP et al. and Sabatine MS. JAMA Cardiol 2017;2:1385-91
  • Giugliano RP et al, Lancet 2017 (on line Aug 28, 2017)
  • Giugliano RP, et al. The Lancet. 2017;390(10106):1962-1971.
  • Schwartz GG, et al. AM Heart J 2014;168:682-689.e1
  • Steg G et al. American College of Cardiology Scientific Sessions, 2018 – Orlando, FL
  • Fonarow JAMA Cardiol 2017;2:1069-78
  • Adapted from Nobel Prize Lecture, Stockholm, Sweden, 1985.
  • Science 1986;232:34
  • Sabatine and Giugliano, JAMA Cardiol 2017;2:935-6